HRD testing for advanced ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study collects tumor samples from people newly diagnosed with advanced ovarian cancer to test for HRD, a genetic feature that may help doctors predict which treatments work best. The goal is to see if HRD testing can guide future treatment decisions for patients like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with high-grade serous ovarian, fallopian tube, or peritoneal cancer that is advanced (stage III or IV) and newly diagnosed.
- You are planning to receive platinum-based chemotherapy as your first treatment.
- You have tumor tissue available from a recent surgery or biopsy taken before starting chemotherapy, with enough sample for testing.
- You are covered by a social security system and have signed a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how women with advanced ovarian cancer respond to treatments based on whether their tumors have a specific DNA repair problem called homologous recombination deficiency (HRD). It aims to understand which treatments work best for different HRD test results.
This Phase 1 study tests HS-10502 in people with advanced solid tumors that have certain DNA repair problems (HRR or HRD). It may help by finding a safe dose and seeing whether the drug can shrink tumors in cancers that have specific genetic features.
This study asks people with advanced ovarian cancer about their preferences for treatment with PARP inhibitors (a type of maintenance therapy). The goal is to learn what matters most to patients for their quality of life.
This study uses a custom lab test on blood (and tumor tissue) to track ovarian cancer returning and to see how well treatment is working. It may help your care team monitor changes over time, especially after certain surgeries.
This trial is a pre-screening process for people with ovarian cancer whose disease came back quickly after platinum chemotherapy (or who cannot take platinum). It may help match you to future study options using a tumor tissue sample.
This study looks at whether a blood test (MRD) can predict how well treatment works for ovarian cancer patients who do not have high CA125 levels, helping doctors choose better therapies.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.